// App-Quantinova.ai

T4154 2016 AHA : Rivaroxaban, but Not PAR-2 Antagonist, Attenuates Cardiac Remodeling Due to Intermittent Hypoxia in Sleep Apnea Model Mice

Researchers

Presenter

  • Ayumi Fujiwara

Principal Investigators

  • Toshiki Kondo

  • Kenji Fujii

  • Hideki Imano

  • Ryuji Kato

  • Yoshio Ijiri

  • Takehiro Yamaguchi

  • Yasukatsu Izumi

  • Minoru Yoshiyama

  • Tetsuya Hayashi

Medical Centers

  • Niigata Univ Sch of Med, Niigata, Japan

  • Osaka Univ Grad Schl of Med, Suita Osaka, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Diastolic dysfunction

  • Arrhythmia

  • Venous thrombosis

Biomarkers

  • Mitogen-activated protein kinase 3

  • Extracellular signal-regulated kinase

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved